First author Cullen Taniguchi, M.D., Ph.D., passed away suddenly before the final publication of this study. A talented physician-scientist motivated by the impact of cancer on his own family, Taniguchi was committed to improving treatment options and outcomes for patients with gastrointestinal cancers as well as mentoring aspiring physicians and scientists.
“Dr. Taniguchi was a pioneer, committed to not accepting the low...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center hosted its inaugural scientific symposium on Nov. 10 at...
The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Data Science in Oncology (IDSO), which integrates the most advanced computational and data science approaches with the institution’s extensive scientific and clinical expertise to significantly improve patient’s lives by transforming cancer care and research.
Bringing top data scientists from a variety of fields together with clinicians...
The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year strategic research collaboration...
ABSTRACTS: 1534, 777, 1328, 1526, 1330, 545
The University of Texas MD Anderson Cancer Center’s Research...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival...
ABSTRACTS: 2359O, 2362MO
Targeted treatment with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib improved responses...
MADRID ― Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy – given before and after surgery...